Prostate Cancer

In response to the findings, The American Cancer Society is launching IMPACT, an initiative aimed at reducing prostate cancer mortality.

“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.

The environmental footprint of prostate MRI and prostate biopsy is similar to a round-trip flight from London to Paris, according to the authors.

In this interview, Arvin K. George, MD, gives an overview of the current state of focal therapy and also discusses 2 clinical trials evaluating new technologies in the space.

"Even though most of the end points had been negative and found no benefit, I think there are a couple of findings that we've learned in 2022 that surprised me," says Mark A. Moyad, MD, MPH.

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”

"[Low-grade prostate cancer] is a really interesting field right now," says Kevin Shee, MD, PhD.

Ashley E. Ross, MD, PhD, provides an overview of his institution’s new protocol for this subset of patients.

“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.

The TAVT-45 formulation of abiraterone acetate was created for patients with dysphagia, who would have difficulty swallowing a tablet.

Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.

“The number of views, viewer engagement, and the length of the video didn't have an impact on the score at all when we did our analysis,” says Daniel Bockelman.

“It's important to put out information that's both accurate and helps to supplement in-office decision making in an outpatient setting,” says Daniel Bockelman.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

Patients can now undergo prostate surgery with epidural anesthesia and light sedation, known as twilight sleep, without the need for a ventilator general anesthesia.

Catch up on all the notable drug and device approvals in urology over the past year.

The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.

Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.

Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.

Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.

The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.